| Literature DB >> 20483193 |
Ciaragh O'Neilla1, Sophie C P Jones1, Janine T Bossé1, Conrad M Watson2, Susanna M Williamson3, Andrew N Rycroft4, J Simon Kroll1, Helen M Hartley2, Paul R Langford1.
Abstract
APXIVA is an RTX toxin of Actinobacillus pleuropneumoniae that is a candidate antigen to differentiate infected from vaccinated animals (DIVA). Insertion of ISApl1 into the apxIVA gene is known to compromise an APXIVA-based DIVA approach, as is potentially a TGG to TGA mutation in the apxIVA gene. ISApl1 was found in 63/349 (18.1%) A. pleuropneumoniae isolates from England and Wales including serovars 2, 3, 6-8 and 12. No ISApl1 insertions into apxIVA were found. Only two serovar 3 isolates contained the TGG to TGA mutation. We conclude that an ApxIVA-based DIVA approach would potentially be viable in England and Wales. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20483193 PMCID： PMC4843962 DOI： 10.1016/j.vaccine.2010.04.113
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641